IRES-C11

• Description:

  IRES-C11 is a spectfic c-MYC internal ribosome entry site (IRES) translation inhibitor. IRES-C11 blocks the interaction of a requisite c-MYC IRES trans-acting factor, heterogeneous nuclear ribonucleoprotein A1, with its IRES. IRES-C11 does not inhibits BAG-1, XIAP and p53 IRESes[1][2].

• UNSPSC:

  12352005

• Hazard Statement:

  H302+H312+H332

• Target:

  C-Myc

• Type:

  Reference compound

• Related Pathways:

  Apoptosis

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/ires-c11.html

• Purity:

  98.01

• Solubility:

  DMSO : 250 mg/mL (ultrasonic)

• Smiles:

  O=C(C(Cl)=C1Cl)N(CC2=CC=C(OC)C=C2OC)C1=O

• Molecular Formula:

  C13H11Cl2NO4

• Molecular Weight:

  316.14

• Precautions:

  H302+H312+H332

• References & Citations:

  [1]Brent Holmes, et al. Mechanistic Target of Rapamycin (mTOR) Inhibition Synergizes with Reduced Internal Ribosome Entry Site (IRES) -mediated Translation of Cyclin D1 and c-MYC mRNAs to Treat Glioblastoma. J Biol Chem. 2016 Jul 1;291 (27) :14146-14159.|[2]Y Shi, et al. Therapeutic potential of targeting IRES-dependent c-myc translation in multiple myeloma cells during ER stress. Oncogene. 2016 Feb 25;35 (8) :1015-24.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [342416-30-2]